Trial Profile
A seamless, sequential Phase III, randomized, multi center single-blind study to evaluate immunogenicity, safety, reactogenicity of liquid ROTAVAC 5C formulation of the live attenuated rotavirus vaccine as a 3-dose series when compared with ROTAVAC® in infants - ROTAVAC 5C
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Rotavirus vaccine (Primary)
- Indications Rotavirus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Bharat Biotech
- 17 Jun 2019 Status changed from recruiting to completed.
- 29 Aug 2016 New trial record